Faricimab + Aflibercept
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Macular Edema
Conditions
Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Trial Timeline
Mar 2, 2021 → Jul 12, 2023
NCT ID
NCT04740931About Faricimab + Aflibercept
Faricimab + Aflibercept is a phase 3 stage product being developed by Chugai Pharmaceutical for Macular Edema. The current trial status is completed. This product is registered under clinical trial identifier NCT04740931. Target conditions include Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04740905 | Phase 3 | Completed |
| NCT04740931 | Phase 3 | Completed |
Competing Products
20 competing products in Macular Edema
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVT aflibercept + Sham SC + SC CLS-TA | Clearside Biomedical | Phase 2 | 44 |
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | 33 |
| 4 mg CLS-TA + Sham + IVT aflibercept | Clearside Biomedical | Phase 2 | 44 |
| suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or Avastin | Clearside Biomedical | Phase 3 | 69 |
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | 44 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | 33 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 1 | 28 |
| FYB203 2 mg (0.05 mL of 40 mg/mL) | Formycon AG | Approved | 77 |
| FYB201 0.5 mg (0.05 mL of 10 mg/mL) | Formycon AG | Approved | 77 |
| UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | 44 |
| UBX1325 | Unity Biotechnology | Phase 2 | 44 |
| Aflibercept + foselutoclax | Unity Biotechnology | Phase 2 | 44 |
| UBX1325 | Unity Biotechnology | Phase 1 | 25 |
| CT-P42 + Eylea | Celltrion | Phase 3 | 77 |
| Faricimab + Aflibercept | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-7080a + Ranibizumab | Daiichi Sankyo | Phase 1 | 33 |
| Fovista® + bevacizumab + ranibizumab + aflibercept | Astellas Pharma | Phase 2 | 52 |
| MA09-hRPE | Astellas Pharma | Pre-clinical | 23 |
| volociximab | Astellas Pharma | Phase 1 | 33 |